Physician profile
John C Showalter
NPI 1104862002
$8,433.07
in general payments reported to CMS, 2019-2025
48 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $681 · 2021: $701 · 2022: $1,498 · 2023: $1,642 · 2024: $1,407 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.68 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,025.34 | 2019-2025 | |
| Novo Nordisk INC | $989.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $746.41 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $589.69 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $305.74 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $295.97 | 2019-2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $293.29 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $281.24 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.17 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $213.75 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $180.59 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $161.11 | 2019-2023 | Belsomra |
| Boston Scientific Corporation | $141.45 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.72 | 2019-2023 | Ofev |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Showalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.